



2022 European Society for Medical Oncology (ESMO) Congress; Paris, France & Online: Eisai Inc. Sponsored Research

Please see the listing of Eisai Inc. sponsored research presented at ESMO 2022 below.

HEPATOCELLULAR CARCINOMA

Finn RS, Kudo M, Merle P, et al. Primary results from the phase 3 LEAP-002 study: lenvatinib plus pembrolizumab versus lenvatinib as first-line therapy for advanced hepatocellular carcinoma. Oral presentation at: the 2022 European Society of Medical Oncology Annual Meeting; September 9-13, 2022; Paris, France.*

RENAL CELL CARCINOMA

Porta CG, Eto M, Motzer RJ, et al. Updated efficacy of lenvatinib plus pembrolizumab versus sunitinib in patients with advanced renal cell carcinoma in the CLEAR Study. Oral presentation at: the 2022 European Society of Medical Oncology Annual Meeting; September 9-13, 2022; Paris, France.*

ENDOMETRIAL CANCER

Makker V, Colombo N, Herraes AC, et al. Updated efficacy and safety of lenvatinib plus pembrolizumab versus treatment of physician's choice in patients with advanced endometrial cancer: Study 309/KEYNOTE-775. Oral presentation at: the 2022 European Society of Medical Oncology Annual Meeting; September 9-13, 2022; Paris, France.*

METASTATIC BREAST CANCER

Kaufman PA, Twelves C, Awada A, et al. Efficacy of eribulin mesylate in HER2-low metastatic breast cancer: results from three phase 3 studies. Poster presented at: the 2022 European Society of Medical Oncology Annual Meeting; September 9-13, 2022; Paris, France.

UROTHELIAL CARCINOMA

Loriot Y, Csozsi T, Matsubara N, et al. Post hoc analysis of pembrolizumab efficacy in potentially platinum-ineligible patients with advanced urothelial carcinoma enrolled in KEYNOTE-052 and LEAP-011. Poster presented at: the 2022 European Society of Medical Oncology Annual Meeting; September 9-13, 2022; Paris, France.*

GASTROESOPHAGEAL ADENOCARCINOMA

Shitara K, Ben-Aharon I, Rojas C, et al. First-line lenvatinib plus pembrolizumab plus chemotherapy versus chemotherapy in advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015 Safety Run-in. Poster presented at: the 2022 European Society of Medical Oncology Annual Meeting; September 9-13, 2022; Paris, France.*

*Funding for this research was provided by Eisai, Inc., Nutley, NJ, USA and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA

IMPORTANT INFORMATION - PLEASE READ:

If you would like a full copy of the publication(s) listed above, please submit your request via www.eisaimedicalinformation.com/oncology/medicalinquiry or the submit a Medical Inquiry Form available on our Medical Information website. Please include specific details: Product(s), Poster Number(s), Author(s), Title(s). You may also email your request to Eisai's Medical Information department at esi_oncmedinfo@eisai.com or call 1-888-274-2378.